Study
EORTC-18071
Adjuvant immunotherapy with anti-CTLA-4 monoclonal antibody (ipilimumab) versus placebo after complete resection of high-risk Stage III melanoma : A randomized, double-blind Phase 3 trial of the EORTC Melanoma Group.
Trial Status
LT-FU ongoing
Dates
Date of activation: 06-May-2008
Date Step1 close: 20-Jul-2011
Date Step2 close: 30-Aug-2011
Date Step1 close: 20-Jul-2011
Date Step2 close: 30-Aug-2011
Data management at EORTC
Yes
Design
Phase 3
Randomized blind
Randomized blind
Targeted Sample size
All Groups: 950
